From Mind To Market - Boehringer Ingelheim

The key to success
For any biopharmaceutical company, negotiating
the path from mind to market is a demanding
process. Very often, the burden of investment and
the complexity in developing and manufacturing
can be prohibitive, especially considering the risk
of failure at the clinical trial stage. Which is why,
companies are increasingly seeking to pool their
economic and intellectual resources by forming
strategic alliances.
We know every step of the way. We have the
resources. The scale of our operation, both in
terms of manufacturing capability and global
presence, befits our status as one of the world’s
leading 20 pharmaceutical companies. We have
the technology. Working in partnership with
Boehringer Ingelheim brings access to a state-ofthe-art
biopharmaceutical environment and a
wealth of accumulated knowledge and specialist
expertise. We have the expertise in process
and analytical sciences for the development of
economical processes with regulatory acceptance.
We have the track record. Many of the
world’s finest biotechnology companies have
achieved success in collaboration with Boehringer
Ingelheim and we can point to a long list
of innovative products already on the market or
in the pipeline due to our expertise.
7